Abstract
Twenty-two patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced squamous cell carcinoma of the head and neck. One patient had a partial response, one an improvement and twenty had progressive disease. The major toxicities were leukopenia and thrombocytopenia. There was no significant antitumor activity of Mitoxantrone in this group of patients with head and neck cancer, most of whom were previously treated with radiation and chemotherapy.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Anthraquinones / adverse effects
-
Anthraquinones / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Drug Evaluation
-
Female
-
Head and Neck Neoplasms / drug therapy*
-
Humans
-
Leukopenia / chemically induced
-
Male
-
Middle Aged
-
Mitoxantrone
-
Thrombocytopenia / chemically induced
Substances
-
Anthraquinones
-
Antineoplastic Agents
-
Mitoxantrone